ALIASSIMINI

COMPOSITION
Asciminib hydrochloride…………………………40mg
INDICATIONS
This product is a kinase inhibitor, suitable for the treatment of
Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), Previously treated with two or more tyrosine kinase inhibitors (TKls).
Ph+ CML in CP with T315I mutation.

PACKAGING:
60 tablets/bottle.

Reg No: 10 L 1221/24
Download ALIASSIMINI Drug Registration Certificate

Brand name: ALIASSIMINI


Composition:
Each tablet contains:
Asciminib hydrochloride…………………………………40mg


Indications:
This product is a kinase inhibitor, suitable for the treatment of
Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), Previously treated with two or more tyrosine kinase inhibitors (TKls).
Ph+ CML in CP with T315I mutation.


Dosage:

  • Recommended Dosage in Ph+ CML in CP; oral, 80 mg once at the same time daily or 40mg twice daily at approximately 12-hour intervals.
  • Recommended Dosage in Ph+ CML in CP with the T315I Mutation: 200mg orally twice daily at approximately 12-hour intervals.
  • Take orally on an empty stomach, at least 2 hours after your last meal or at least 1 hour before your next meal.
  • Continue treatment with ALIASSIMINI until disease progression or unacceptable toxicity occurs.

Contraindications:

  • Patients who are allergic to the active ingredients or any excipients of this product.

Warnings:

  • Myelosuppression: Severe thrombocytopenia and neutropenia events may occur. Monitor complete blood counts regularly during therapy and manage by treatment interruption or dose reduction.
  • Pancreatic toxicity: Monitor serum lipase and amylase. Interrupt, then resume at reduced dose or stop administration based on severity.
  • Hypersensitivity: May cause hypersensitivity reactions.
  • Cardiovascular Toxicity: Cardiovascular toxicity may occur.
  • Embryo-Fetal Toxicity: Can cause fetal harm.

Adverse Effects:
Upper respiratory tract infection, musculoskeletal pain, high blood pressure, low blood cell count, elevated uric acid, headache, fatigue, nausea, rash, diarrhea.


Dosage form: Light red tablets.


Expiry date: 24 months after date of manufacture.


Packaging:

  • 60 tablets/bottle.

Storage:

  • Protected from light, sealed, and stored at 20℃- 25℃.
  • Keep out of reach of children.

DISCLAIMER

The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.

For your safety:

Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.